SGHT SIGHT SCIENCES INC

Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2022, after the market close on Thursday, August 11, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the audio webcast should register online . Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at , in the News & Events section.

About Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by an eye care professional to address the leading cause of dry eye disease.

For more information, visit .

OMNI® and TearCare® are registered trademarks of Sight Sciences.

© 2022 Sight Sciences. All rights reserved.

Investor contact:

Philip Taylor

Gilmartin Group

415.937.5406



EN
28/07/2022

Underlying

SGHTSIGHT SCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SIGHT SCIENCES INC

 PRESS RELEASE
Free
SGHT SIGHT SCIENCES ...

New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgic...

New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of Cataract and Refractive Surgery, Journal of Glaucoma and Clinical Ophthalmology MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developi...

November 11, 2025 1 EN
 PRESS RELEASE
Free
SGHT SIGHT SCIENCES ...

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises...

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025. Recent Financial and Busines...

November 6, 2025 1 EN
 PRESS RELEASE
Free
SGHT SIGHT SCIENCES ...

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and J...

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauer...

November 6, 2025 1 EN
 PRESS RELEASE
Free
SGHT SIGHT SCIENCES ...

Sight Sciences to Present at Two Upcoming Investor Conferences

Sight Sciences to Present at Two Upcoming Investor Conferences MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Stifel 2025 Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference, both in New York, NY. Sight Sciences’ management is scheduled to present at the Stifel 2025 Healthcare Conference ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
SGHT SIGHT SCIENCES ...

Sight Sciences to Report Third Quarter 2025 Financial Results on Novem...

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025 MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 6, 2025. The Company’s management will discuss the results during a conference call beginning ...

October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch